Proteon Therapeutics Company Profile (NASDAQ:PRTO)

About Proteon Therapeutics

Proteon Therapeutics logoProteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PRTO
  • CUSIP:
Key Metrics:
  • Previous Close: $9.95
  • 50 Day Moving Average: $8.59
  • 200 Day Moving Average: $7.54
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.93
  • P/E Growth: 0.00
  • Market Cap: $164.99M
  • Outstanding Shares: 16,582,000
  • Beta: 2.31
Additional Links:
Companies Related to Proteon Therapeutics:

Analyst Ratings

Consensus Ratings for Proteon Therapeutics (NASDAQ:PRTO) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.50 (116.08% upside)

Analysts' Ratings History for Proteon Therapeutics (NASDAQ:PRTO)
Show:
DateFirmActionRatingPrice TargetDetails
4/13/2016Robert W. BairdInitiated CoverageOutperform$20.00View Rating Details
3/15/2016Stifel NicolausLower Price TargetBuy$20.00 -> $19.00View Rating Details
3/9/2016JMP SecuritiesBoost Price TargetMarket Outperform$22.00 -> $27.00View Rating Details
11/10/2015Raymond James Financial Inc.Initiated CoverageOutperform$20.00View Rating Details
11/17/2014Oppenheimer Holdings Inc.Initiated CoverageOutperform$18.00View Rating Details
(Data available from 8/24/2014 forward)

Earnings

Earnings History for Proteon Therapeutics (NASDAQ:PRTO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
8/8/2016($0.43)($0.48)ViewN/AView Earnings Details
5/9/2016Q1($0.41)($0.40)ViewN/AView Earnings Details
3/14/2016($0.34)($0.39)ViewN/AView Earnings Details
11/12/2015Q315($0.33)($0.33)ViewN/AView Earnings Details
8/13/2015Q215($0.30)($0.31)ViewN/AView Earnings Details
5/13/2015($0.24)($0.28)ViewN/AView Earnings Details
3/20/2015($0.26)($0.24)ViewN/AView Earnings Details
11/26/2014($0.31)($31.03)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Proteon Therapeutics (NASDAQ:PRTO)
Current Year EPS Consensus Estimate: $-1.87 EPS
Next Year EPS Consensus Estimate: $-2.02 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.42)($0.42)($0.42)
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.46)($0.46)($0.46)
Q4 20161($0.50)($0.50)($0.50)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Proteon Therapeutics (NASDAQ:PRTO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Proteon Therapeutics (NASDAQ:PRTO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/6/2016George Arthur EldridgeCFOBuy4,000$5.78$23,120.00View SEC Filing  
12/1/2015Timothy P. NoyesCEOSell5,000$14.97$74,850.00View SEC Filing  
11/2/2015Timothy P. NoyesCEOSell5,000$13.50$67,500.00View SEC Filing  
10/1/2015Timothy P. NoyesCEOSell5,000$13.33$66,650.00View SEC Filing  
9/8/2015Timothy P. NoyesCEOSell5,000$13.55$67,750.00View SEC Filing  
7/7/2015Daniel Philip GottliebVPSell1,965$16.86$33,129.90View SEC Filing  
10/27/2014James E FlynnInsiderBuy691,713$10.00$6,917,130.00View SEC Filing  
10/27/2014Skyline Venture Partners QualiMajor ShareholderSell56,038$10.00$560,380.00View SEC Filing  
10/27/2014Timothy HainesDirectorBuy950,000$10.00$9,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Proteon Therapeutics (NASDAQ:PRTO)
DateHeadline
globenewswire.com logoProteon Therapeutics Announces Second Quarter 2016 Financial Results (NASDAQ:PRTO)
globenewswire.com - August 8 at 7:11 PM
twst.com logoProteon Therapeutics Inc.: Proteon Therapeutics Announces Second Quarter 2016 Financial Results (NASDAQ:PRTO)
www.twst.com - August 8 at 7:11 PM
sg.finance.yahoo.com logoProteon Therapeutics reports 2Q loss (NASDAQ:PRTO)
sg.finance.yahoo.com - August 8 at 11:40 AM
thestreet.com logo7 Stocks Under $10 to Trade for Big Post-Brexit Gains (NASDAQ:PRTO)
www.thestreet.com - August 3 at 10:11 AM
seekingalpha.com logoHave You Ever Heard Of Proteon Therapeutics? (NASDAQ:PRTO)
seekingalpha.com - July 19 at 7:05 PM
finance.yahoo.com logoProteon Therapeutics (PRTO) in Focus: Stock Gains 6.4% (NASDAQ:PRTO)
finance.yahoo.com - June 24 at 8:45 AM
publicnow.com logoProteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 22nd (NASDAQ:PRTO)
www.publicnow.com - June 15 at 8:29 AM
biz.yahoo.com logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:PRTO)
biz.yahoo.com - June 13 at 8:01 AM
capitalcube.com logoProteon Therapeutics, Inc. :PRTO-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 (NASDAQ:PRTO)
www.capitalcube.com - June 8 at 6:07 PM
sg.finance.yahoo.com logoProteon Therapeutics reports 1Q loss (NASDAQ:PRTO)
sg.finance.yahoo.com - May 9 at 8:28 AM
publicnow.com logoProteon Therapeutics Announces First Quarter 2016 Financial Results (NASDAQ:PRTO)
www.publicnow.com - May 9 at 8:18 AM
biz.yahoo.com logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:PRTO)
biz.yahoo.com - May 9 at 8:02 AM
publicnow.com logoProteon Therapeutics Announces Survey Findings Demonstrating Impact of Vascular Access Failure on Hemodialysis Patients (NASDAQ:PRTO)
www.publicnow.com - April 28 at 7:22 AM
finance.yahoo.com logoCoverage initiated on Proteon Therapeutics by Robert W. Baird (NASDAQ:PRTO)
finance.yahoo.com - April 14 at 5:41 AM
feeds.benzinga.com logoProteon Therapeutics Reports Publication of Promising Nonclinical Results from Vonapanitase in Peripheral Artery Disease (NASDAQ:PRTO)
feeds.benzinga.com - April 13 at 9:33 AM
publicnow.com logoProteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease (NASDAQ:PRTO)
www.publicnow.com - April 13 at 8:24 AM
sg.finance.yahoo.com logoProteon Therapeutics reports 4Q loss (NASDAQ:PRTO)
sg.finance.yahoo.com - March 14 at 8:57 AM
finance.yahoo.com logoProteon Therapeutics Announces Fourth Quarter and Full-Year 2015 Financial Results (NASDAQ:PRTO)
finance.yahoo.com - March 14 at 8:30 AM
finance.yahoo.com logoProteon Therapeutics to Present at the 2016 BIO CEO & Investor Conference February 8th (NASDAQ:PRTO)
finance.yahoo.com - February 2 at 8:00 AM
biz.yahoo.com logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:PRTO)
biz.yahoo.com - January 22 at 8:31 AM
finance.yahoo.com logoPROTEON THERAPEUTICS INC Financials (NASDAQ:PRTO)
finance.yahoo.com - December 8 at 1:17 PM
finance.yahoo.com logoProteon Therapeutics to Present at the Oppenheimer 26th Annual Healthcare Conference December 9th (NASDAQ:PRTO)
finance.yahoo.com - December 2 at 8:00 AM
finance.yahoo.com logoProteon Therapeutics to Present at the Stifel 2015 Healthcare Conference on November 17th (NASDAQ:PRTO)
finance.yahoo.com - November 13 at 7:45 AM
biz.yahoo.com logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh (NASDAQ:PRTO)
biz.yahoo.com - November 12 at 4:17 PM
sg.finance.yahoo.com logoProteon Therapeutics reports 3Q loss (NASDAQ:PRTO)
sg.finance.yahoo.com - November 12 at 9:25 AM
noodls.com logoProteon Therapeutics Announces Third Quarter 2015 Financial Results (NASDAQ:PRTO)
www.noodls.com - November 12 at 8:26 AM
finance.yahoo.com logoProteon Therapeutics to Host Research and Development Day on November 20, 2015 (NASDAQ:PRTO)
finance.yahoo.com - November 9 at 11:58 AM
biz.yahoo.com logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:PRTO)
biz.yahoo.com - November 2 at 4:17 PM
finance.yahoo.com logoProteon Therapeutics Completes Enrollment in PATENCY-1, First Phase 3 Clinical Study of Investigational Vonapanitase (NASDAQ:PRTO)
finance.yahoo.com - November 2 at 4:15 PM
finance.yahoo.com logoProteon Therapeutics to Present at the BIO-Europe 2015 Conference November 3 (NASDAQ:PRTO)
finance.yahoo.com - October 28 at 5:00 PM
noodls.com logoProteon Therapeutics Appoints Tony Kingsley to Its Board of Directors (NASDAQ:PRTO)
www.noodls.com - October 19 at 8:31 AM
biz.yahoo.com logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi (NASDAQ:PRTO)
biz.yahoo.com - October 19 at 8:02 AM
noodls.com logoProteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015 (NASDAQ:PRTO)
www.noodls.com - October 12 at 8:25 AM

Social

Proteon Therapeutics (NASDAQ:PRTO) Chart for Wednesday, August, 24, 2016


Last Updated on 8/24/2016 by MarketBeat.com Staff